Global Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Global · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.43 BnPlaceholder estimate
Estimate 2025$1.57 BnPlaceholder estimate
Projected 2034$3.71 Bn 135.8%Adds $2.14 Bn over 9 forecast years
CAGR 2025–203410.0%Faster than 57% of 173 Medical Devices markets here
588 worldwideSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Global Neuromodulation for Depression Market Analysis Executive Summary
Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.
Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).
Global Neuromodulation for Depression market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Global Neuromodulation for Depression Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.
Competitive Landscape for Neuromodulation for Depression Market in Global
The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in Global
Neuromodulation for Depression worldwide: rules, payment and research
There is no single global regulator; the International Medical Device Regulators Forum (IMDRF) helps national regulators align their device rules.[1] WHO reports that 4.5 billion people were not fully covered by essential health services in 2021.[2] ClinicalTrials.gov lists 588 studies on Neuromodulation for Depression that are recruiting, active or about to start worldwide.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Global.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Technology
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Neuronetics
7.2 BrainsWay
7.3 Magstim
7.4 LivaNova
7.5 Flow Neuroscience
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The neuromodulation for Depression market can be segmented based on various criteria, including technology, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.
How big is the Neuromodulation for Depression market worldwide?
Placeholder estimate: about $1.57 Bn in 2025, rising to about $3.71 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuromodulation for Depression market worldwide growing?
Placeholder estimate: about 10.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuromodulation for Depression market report cover?
The report splits the market by technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, tDCS), setting (Clinics, Hospitals, Home) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Neuromodulation for Depression market?
Key players include Neuronetics, BrainsWay, Magstim, LivaNova PLC and Flow Neuroscience.
What is driving the Neuromodulation for Depression market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Who regulates Neuromodulation for Depression worldwide?
There is no single global regulator; the International Medical Device Regulators Forum (IMDRF) helps national regulators align their device rules. Source: International Medical Device Regulators Forum. Checked 14 Nov 2026.
How many clinical trials on Neuromodulation for Depression are running worldwide?
588 studies are recruiting, active or about to start worldwide, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
How much research is published on Neuromodulation for Depression?
PubMed lists 74 papers on Neuromodulation for Depression added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
India
China
Canada
Japan
Germany
UK
France
Brazil
Italy
Spain
Ecuador
Saudi Arabia
Mexico
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya